### Thursday, 9 May 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00/13:15</td>
<td><strong>Official welcome and opening of the Conference</strong></td>
<td><strong>AUDITORIUM A</strong></td>
</tr>
<tr>
<td>13:15/13:45</td>
<td><strong>Keynote lecture</strong></td>
<td><strong>AUDITORIUM A</strong></td>
</tr>
<tr>
<td>13:15</td>
<td>Intratumour heterogeneity and evolution: Opportunities for therapy</td>
<td><strong>AUDITORIUM A</strong></td>
</tr>
<tr>
<td>13:45/15:15</td>
<td><strong>Molecular pathology of non-small cell lung cancer</strong></td>
<td><strong>AUDITORIUM A</strong></td>
</tr>
<tr>
<td>13:45</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>13:50</td>
<td>Molecular characteristics of lung adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>14:10</td>
<td>Molecular characteristics of lung squamous cell carcinoma</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Challenges of biomarker testing with IHC and FISH</td>
<td></td>
</tr>
<tr>
<td>14:50</td>
<td>Opportunities, limitations and implications of new genome sequencing</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>Conclusions / Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>15:45/17:15</td>
<td><strong>Diagnostic work-up</strong></td>
<td><strong>AUDITORIUM A</strong></td>
</tr>
<tr>
<td>15:45</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>15:50</td>
<td>Getting tissue in the era of molecular treatment</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>PET-CT for lung nodules: Opportunities and pitfalls</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Reliable lung nodule identification during VATS</td>
<td></td>
</tr>
</tbody>
</table>
Friday, 10 May 2013

08:00/09:00 Early and locally advanced disease
Chair: Kevin Franks, Leeds, UK
and Paul Van Schil, Edegem, Belgium

08:00 T1bN0M0 in a “marginally operable” patient: Surgery
Paul Van Schil, Edegem, Belgium

08:30 T1bN0M0 in a “marginally operable” patient: SABR
Kevin Franks, Leeds, UK

08:00/09:00 Advanced disease
Chair: Federico Cappuzzo, Livorno, Italy
and Jean-Paul Sculier, Brussels, Belgium

08:00 When to stop TKI treatment in NSCLC with driver mutation?
- Pneumology
Jean-Paul Sculier, Brussels, Belgium

08:30 When to stop TKI treatment in NSCLC with driver mutation?
- Medical Oncology
Federico Cappuzzo, Livorno, Italy

08:00/09:00 Poster Discussion:
Biology and targeted therapy
Chair: Thierry Berghmans, Brussels, Belgium
and Nicola Normanno, Naples, Italy

70PD - Effect of enobosarm, a selective androgen receptor
modulator, in non-small cell lung cancer (NSCLC) patients
with muscle wasting in a phase Ib trial
Mitchell Steiner, Memphis, TN, US

40PD - Small cell lung cancer and hyponatremia: Interim
results from a prospective, observational, global registry
Andrew Makin, Uxbridge, UK

08:00 Discussant abstracts 70PD and 40PD
Thierry Berghmans, Brussels, Belgium

08:10 Questions to Discussant
71PD - Reversible epidermal growth factor receptor tyrosine kinases inhibitors (rEGFR-TKIs), erlotinib or gefitinib, compared to chemotherapy (CHT) in previously treated metastatic non small cell lung cancer (NSCLC) patients (pts): A meta-analysis
Alessia Pochesci, Rome, Italy

72PD - Impact of EGFR status on the presence of liver metastases (LM) from non-small cell lung cancer (NSCLC) and survival implications
Eduardo Castañón Alvarez, Pamplona, Spain

26PD - Foretinib (GSK1363089), a multikinase inhibitor of MET and VEGFs, overcomes resistance to bevacizumab in an in vivo model of acquired bevacizumab resistance
Mian Xie, Guangzhou, China

08:20 Discussant abstracts 71PD, 72PD and 26PD
Kostas Syrigos, Athens, Greece

08:30 Questions to Discussant

24PD - Metabolomic profile of lung cancer patients
Leonor Puchades-Carrasco, Valencia, Spain

25PD - Circulating micro-RNA profiling in patients with advanced non-squamous non small-cell lung cancer receiving bevacizumab/erlotinib first-line treatment followed by platinum-based chemotherapy at disease progression (SAKK19/05)
Markus Joerger, St. Gallen, Switzerland

2PD - Isolation and characterization of circulating tumour cells in advanced squamous-cell carcinoma of the lung
Cecilia Bozzetti, Parma, Italy

08:40 Discussant abstracts 24PD, 25PD and 2PD
Nicola Normanno, Naples, Italy

08:50 Questions to Discussant

09:15/10:30 Early-drug development in lung cancer
AUIDITORIUM A
Chairs: Alex A. Adjei, Buffalo, NY, US and Enriqueta Felip, Barcelona, Spain

09:15 Challenges in designing phase I trials in the era of targeted therapies
Alex A. Adjei, Buffalo, NY, US

09:35 Phase I studies in the broad cancer population vs selected patients
Benjamin Besse, Villejuif, France

09:55 How should we utilize biomarkers in phase I trials?
Enriqueta Felip, Barcelona, Spain

10:15 Panel Discussion

10:30 Coffee Break
11:00/12:30 Early stage NSCLC (Stages I & II) **AUDITORIUM A**
Chairs: Lucio Crinò, Perugia, Italy and Gaetano Rocco, Naples, Italy

11:00 Introduction
11:05 Treatment of octogenarians
Gaetano Rocco, Naples, Italy
11:25 Sublobar resection
Henrik J. Hansen, Copenhagen, Denmark
11:45 SABR for centrally located tumours
Suresh Senan, Amsterdam, Netherlands
12:05 Is lobectomy by VATS or by robot the surgical standard?
Thomas Schmid, Innsbruck, Austria
12:25 Conclusions / Q&A

11:00/12:30 Proffered Papers: Systemic therapy **ROOM B**
Chair: Luis Paz-Ares, Seville, Spain
Co-Chair: Martin Reck, Grosshansdorf, Germany

11:00 **67O** - Are first-line platinum-based (PT) regimens improving survival in comparison with non-platinum (NPT) chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC)? A meta-analysis (MA) of randomised trials
Thierry Berghmans, Brussels, Belgium

11:10 **68O** - Efficacy, safety and tolerability results from a phase IV, open-label, single arm study of 1st-line gefitinib in Caucasian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC)
Jean-Yves Douillard, St. Herblain, France

11:20 **36O** - 99mTc-etarfolatide (EC20) imaging to identify NSCLC patients likely to benefit from vintafolide (EC145) treatment
Weal Harb, Lafayette, IN, US

11:30 Discussant abstracts 67O, 68O and 36O
Elisabeth Quoix, Strasbourg, France

11:45 **69O** - Molecular follow up of an Italian cohort of EGFR mutated patients progressing after treatment with oral tyrosine kinase inhibitors
Bruno Gori, Rome, Italy

11:55 **22O** - Rebiopsy in TKI-resistance; A retrospective analysis
Justine Kuiper, Amsterdam, Netherlands

12:05 **65O** - Her2 in non-small cell lung carcinomas
Zoran Gatalica, Phoenix, AZ, US

12:15 Discussant abstracts 69O, 22O and 65O
Luis Paz-Ares, Seville, Spain

12:30/13:00 Lunch & Poster Display session
Please refer to page 27 for details
13:00/14:00  Treatment strategies in NSCLC: Shaping clinical practice  
Room B
Roche Satellite Symposium
Please refer to page 39 for details

14:00/15:30  Stage III NSCLC  
Auditorium A
Chairs: Wilfried Eberhardt, Essen, Germany and Walter Weder, Zurich, Switzerland

14:00  Introduction

14:05  Is surgery indicated in persistent N2 after neoadjuvant treatment?  
Walter Weder, Zurich, Switzerland

14:25  Is post-operative RT necessary in completely resected patients with mediastinal involvement?  
Cecile Le Pechoux, Villejuif, France

14:45  Integrating targeted treatment in a neoadjuvant approach: Opportunities and risks  
Enriqueta Felip, Barcelona, Spain

15:05  How to improve cure rates of chemoradiotherapy for stage III treatment in European populations  
Dirk De Ruyscher, Maastricht, Netherlands

15:25  Conclusions / Q&A

14:15/15:30  Proffered Papers: Diagnosis and pathology  
Room B
Chair: Stephen Finn, Dublin, Ireland  
Co-Chair: Giulia Veronesi, Milan, Italy

14:15  10 - The LungPath Study - Optimising the pathological diagnosis of lung cancer  
Paul Cane, London, UK

14:25  230 - Serum microrna as a diagnostic test for early lung cancer  
Giulia Veronesi, Milan, Italy

14:35  Discussant abstracts 10 and 230  
Stephen Finn, Dublin, Ireland

14:45  660 - EGFR mutated patients (pts): Different pattern and outcome of metastatic bone disease (MBD) and brain metastasis (BM)?  
Lizza Hendriks, Maastricht, Netherlands

14:55  Discussant abstract 660  
Benjamin Besse, Villejuif, France

15:05  150 - Volumetric computer tomography screening for lung cancer: Three rounds of the NELSON trial  
Nanda Horeweg, Rotterdam, Netherlands

15:15  Discussant abstract 150  
Giulia Veronesi, Milan, Italy

15:25  General Q&A
15:30/15:50 San Salvatore Foundation Award
Chairs: Luigi Butti, Lugano, Switzerland
and Rolf A. Stahel, Zurich, Switzerland

15:50 Coffee Break

16:10/17:10 Immunotherapy of non-small cell lung cancer
Chairs: Solange Peters, Lausanne, Switzerland
and Rolf A. Stahel, Zurich, Switzerland

16:10 Vaccination approaches to NSCLC
Johan Vansteenkiste, Leuven, Belgium

16:25 Novel immunotherapy treatment approaches in non-small cell lung cancer
Naiyer Rizvi, New York, NY, US

16:45 Combination therapies in non-small cell lung cancer
Martin Reck, Grosshansdorf, Germany

17:00 Conclusions / Q&A
This session is kindly supported by an unrestricted educational grant from BMS

17:10/18:20 SCLC and Thymoma
Moderators: Cecile Le Pechoux, Villejuif, France
and Enrico Ruffini, Turin, Italy

17:10 Thymoma treatment – A European overview
Enrico Ruffini, Turin, Italy

17:25 Thymoma biology
Nicholas Girard, Lyon, France

17:40 Controversies in surgical treatment of thymoma
Walter Klepetko, Vienna, Austria

17:55 Ongoing trials in SCLC and what we can expect
Corinne Faivre-Finn, Withington, Manchester, UK

18:10 Conclusions / Q&A

17:10/18:00 Mesothelioma
Chairs: Paul Baas, Amsterdam, Netherlands
and Isabelle Opitz, Zurich, Switzerland

17:10 What did we learn from multimodality treatment?
Isabelle Opitz, Zurich, Switzerland

17:25 Is there a standard surgical approach within multimodality treatment?
Laureano Molins, Barcelona, Spain

17:40 New insights in mesothelioma biology: Are there clinical implications?
Emanuela Felley-Bosco, Zurich, Switzerland

17:55 Conclusions / Q&A
Paul Baas, Amsterdam, Netherlands
Saturday, 11 May 2013

08:00/09:00  **Radical approach to oligometastatic disease**  
**AUDITORIUM A**  
Chairs: Elisabeth Quoix, Strasbourg, France and Johan Vansteenkiste, Leuven, Belgium

08:00  A patient with synchronous isolated adrenal gland metastasis and right upper lobe T1aN2 adenocarcinoma  
Virginie Westeel, Besancon, France

08:30  A patient with T2aN2 adenocarcinoma and one brain and one contralateral rib metastasis  
Dirk De Ruysscher, Maastricht, Netherlands

08:00/09:00  **Locally advanced disease**  
**ROOM B**  
Chairs: Max Dahele, Amsterdam, Netherlands and Lorenzo Spaggiari, Milan, Italy

08:00  Re-irradiation following a local recurrence in stage III NSCLC  
Max Dahele, Amsterdam, Netherlands

08:30  Salvage therapy in locally advanced NSCLC progressive after neoadjuvant treatment  
Lorenzo Spaggiari, Milan, Italy

08:00/09:00  **Poster Discussion: Risk factors and combined modality therapy**  
**ROOM C**  
Chairs: Mina Gaga, Athens, Greece and Walter Klepetko, Vienna, Austria

**38PD** - Current role of VATS in the diagnosis of a mediastinal lymphadenopathy of unknown etiology  
Felice Lo Faso, Ravenna, Italy

**57PD** - Neoadjuvant chemoradiotherapy for locally advanced nonsmall cell lung cancer  
Alper Toker, Istanbul, Turkey

**58PD** - VATS lobectomy after induction therapy for lung cancer: A safe and effective method  
Yi C. Wu, Taoyuan, Taiwan

**59PD** - Pre- and intraoperative photodynamic therapy in locally advanced central NSCLC  
Andrey Akopov, Saint Petersburg, Russian Federation

08:00  Discussant abstracts 38PD, 57PD, 58PD and 59PD  
Walter Klepetko, Vienna, Austria

08:15  Questions to Discussant

**123PD** - Prognostic and predictive factors in patients with lung cancer and brain metastases  
Bozena Jochymek, Gliwice, Poland

**122PD** - Age specific risk assessment in senior lung cancer patients  
Nazar Lukavetskyy, Lviv, Ukraine
96PD - Pattern and survival of lung metastasis in young breast cancer patients: A single centre experience
Ajay Gogia, New Delhi, India

08:30 Discussant abstracts 123PD,122PD and 96PD
Mina Gaga, Athens, Greece

08:45 Questions to Discussant

09:10/10:40 Personalised treatment of advanced disease
Chairs: Solange Peters, Lausanne, Switzerland
and Jean-Paul Sculier, Brussels, Belgium

09:10 Introduction

09:15 EGFR TKI
Solange Peters, Lausanne, Switzerland

09:35 ALK/ROS1
Silvia Novello, Orbassano-Torino, Italy

09:55 Other targets in adenocarcinoma
Ken O’Byrne, Dublin, Ireland

10:15 Other targets in squamous cell carcinoma
Martin Reck, Grosshansdorf, Germany

10:35 Conclusions / Q&A

Financial support for this Educational Session has been provided by Lilly

09:10/10:40 Proffered Papers: Combined modality therapy
Chair: Cecile Le Pechoux, Villejuif, France
Co-Chair: Paul Van Schil, Edegem, Belgium

09:10 480 - Treatment of multiple primary lung cancers (MLPC) with stereotactic ablative radiotherapy (SABR)
Gwendolyn Griffioen, Amsterdam, Netherlands

09:20 500 - Predictors for radiation pneumonitis after SABR for high-risk lung tumours
Eva Bongers, Amsterdam, Netherlands

09:30 560 - Outcomes of concurrent chemo-radiotherapy for large-volume stage III NSCLC
Max Dahele, Amsterdam, Netherlands

09:40 Discussant abstracts 480, 500 and 560
Cecile Le Pechoux, Villejuif, France

09:55 950 - Surgical treatment of 549 patients with lung metastases from colorectal carcinoma. Initial results of a prospective Spanish study
Laureano Molins, Barcelona, Spain
10:05 370 - 18-F FDG PET total glycolytic volume in thymic epithelial neoplasms evaluation: An easily reproducible image biomarker
Luca Bertolaccini, Cuneo, Italy

10:15 490 - Lungtransplantation in early stage carcinoma of the explanted lung - Is it a cure for the cancer?
Thomas Klikovits, Vienna, Austria

10:25 Discussant abstracts 370 and 490
Paul Van Schil, Edegem, Belgium

10:40 Coffee Break

11:00/12:00 What are the requirements for a thoracic oncology centre?
Chairs: Enriqueta Felip, Barcelona, Spain and Jean Paul Sculier, Brussels Belgium

11:00 Screening
Giulia Veronesi, Milan, Italy

11:20 Radiotherapy
Daniel Zips, Dresden, Germany

11:40 Surgery
Bernward Passlick, Freiburg, Germany

12:00/13:00 Advances and perspectives for 2013 onwards
Chairs: Enriqueta Felip, Barcelona, Spain and Rolf A. Stahel, Zurich, Switzerland

12:00 What is emerging in biomarker testing?
Nicola Normanno, Naples, Italy

12:20 What is on the horizon for personalised treatment?
Luis Paz-Ares, Seville, Spain

12:40 What are the consequences for the design of clinical trials?
Tony S.K. Mok, Hong Kong, China

13:00/13:30 Keynote Lecture
Chair: Enriqueta Felip, Barcelona, Spain

13:00 Combining knowledge towards personalized treatment by a multidisciplinary team
Rolf A. Stahel, Zurich, Switzerland

13:30/13:45 Closing remarks

13:45 Light lunch
Thursday, 9 May 2013

17:30/18:30 SOCIETY SYMPOSIUM
European Thoracic Oncology Platform (ETOP)
Chairs: Solange Peters, Lausanne, Switzerland and Rolf A. Stahel, Zurich, Switzerland

17:30 Lungscape
Rolf A. Stahel, Zurich, Switzerland

17:45 BELIEF
Rafael Rosell, Badalona, Spain

18:00 EMPHASIS
Solange Peters, Lausanne, Switzerland

18:15 Emerging projects
Solange Peters, Lausanne, Switzerland

Friday, 10 May 2013

13:00/14:00 INDUSTRY SATELLITE SYMPOSIUM
Roche
Treatment strategies in NSCLC: Shaping clinical practice
Chairs and Panel: Solange Peters, Lausanne, Switzerland and Martin Reck, Grosshansdorf, Germany

12:50 Welcome

12:55 Getting to maintenance: Spotlight on anti-VEGF therapy
Martin Reck, Grosshansdorf, Germany

13:10 Q&A
Panel

13:20 A clear perspective on the role of EGFR TKIs
Solange Peters, Lausanne, Switzerland

13:40 Q&A
Panel

13:50 Close